Imperial Brands (IMB): What the Fundamentals Show in Five Markets

Few FTSE 100 constituents divide opinion quite as sharply as the owner of Davidoff, West, Gauloises and Winston. Any honest Imperial Brands stock analysis has to start from an uncomfortable fact: the group sells a product whose volumes shrink almost every year, in markets where regulation tightens almost every year, and it still throws off billions of pounds in cash while doing so. Understanding how those two things coexist is the whole exercise. This article walks through where the revenue actually comes from, what the most recent reported figures show, how the cash is being spent, and which indicators would change the picture from here. Imperial Brands shares trade on the London Stock Exchange under the ticker IMB, and all prices quoted below are in pence unless stated otherwise.

How Imperial Brands Makes Its Money

Imperial Brands is organised around two very different businesses. The larger one is tobacco and next generation products, which is the branded nicotine business most investors have in mind. The smaller one is Distribution, which consists of the group's 50.01% stake in Logista, a Spanish-listed logistics operator that moves tobacco and convenience goods to retailers and also runs freight, parcel, courier and pharmaceutical logistics networks.

Within the branded business, the strategic centre of gravity is a set of five markets the company calls its priority markets: the United States, Germany, the United Kingdom, Spain and Australia. These five accounted for roughly 70% of adjusted tobacco operating profit, which tells you something important about the shape of the organisation. Imperial is not attempting to be strong everywhere. It is attempting to defend share in a handful of large, high-margin, relatively stable markets, and to run the rest of its footprint for cash.

That strategy has a measurable scorecard. Across FY2025, aggregate market share in the five priority markets was broadly stable, with gains in Germany and Australia offsetting declines in the United States, the United Kingdom and Spain. On a cumulative basis since FY2020, aggregate share in those top five markets has risen by 48 basis points. For a company in a structurally declining category, holding share rather than gaining it is the realistic goal, and the share line is therefore one of the most informative single numbers in the whole reporting pack.

The third leg is next generation products, or NGP: vapour under the blu brand, modern oral nicotine pouches under Zone, and heated tobacco under Pulze and the iSenzia stick range. NGP is still small in absolute terms. In FY2025 it generated £368m of net revenue, up 13.7% at constant currency, against tobacco and NGP net revenue of £8,316m for the segment as a whole. Growth in the Americas accelerated sharply, with NGP revenue there up 69.8% on the back of Zone's expansion in modern oral, while Europe grew 8.8% as blu held double-digit vapour share in markets including the United Kingdom, Spain and France.

What the FY2025 Figures Showed

Imperial Brands operates a 30 September financial year end, and FY2025 results were published on 18 November 2025. Reported revenue, which includes tobacco duty and the gross flows through Logista, was £32,171m, down 0.7% on the prior year. That headline number is close to meaningless for assessing the business, which is why management reports tobacco and NGP net revenue separately: that figure was £8,316m, up 1.9% as reported and 4.1% at constant currency.

Adjusted operating profit for FY2025 came in at £3,988m, up 4.6% at constant currency and 2.0% at actual rates. Reported operating profit was lower at £3,490m, the gap reflecting adjusting items that management strips out of its underlying measures. Adjusted earnings per share reached 315.0p, up 9.1% at constant currency, with the buyback programme reducing the share count and amplifying the profit growth into a larger per-share gain.

The Distribution segment contributed gross profit of £1,530m, up 1.8% as reported, but segment adjusted operating profit slipped to £316m from £330m and the margin narrowed to 20.7% from 22.0%. Management attributed that to weakness in transportation offsetting strong tobacco and pharmaceutical volumes. After eliminations, Logista's contribution to group adjusted operating profit was £323m against £324m the year before. It is a modest contributor to profit but a useful one, because its economics are not tied to nicotine consumption.

The First Half of FY2026 and the One Off Charges

Half-year results for the six months to 31 March 2026 were reported on 12 May 2026, and they are a good illustration of why reported and adjusted figures can tell such different stories. Reported revenue was £14,719m, up 0.8% from £14,604m. Tobacco and NGP net revenue was £3,730m, up 1.8% at constant currency. Adjusted operating profit was £1,644m, essentially flat against £1,652m a year earlier, and adjusted earnings per share rose 5.3% to 127.7p, again helped by the shrinking share count.

The reported figures looked very different. Reported operating profit fell 36.5% to £925m and reported earnings per share dropped 38.1% to 59.9p. Two items explain most of that: £313m of charges relating to the Delaware settlement and £210m relating to the implementation of the group's 2030 Strategy. Of the Delaware amount, £150m was paid in cash during the half.

The 2030 Strategy charges are a deliberate, guided spend rather than a surprise. Management has framed the programme as rationalising the manufacturing footprint, improving operational efficiency and investing in technology, with the exit from the Langenhagen site in Germany cited as an example, and it is targeting £320m of annual cost savings by 2030. Further costs will land as adjusting items in future periods, so investors reading reported profit alone should expect the gap between reported and adjusted figures to persist for several years. Anyone conducting their own Imperial Brands stock analysis needs to decide how much of that restructuring spend they treat as genuinely one-off and how much as a recurring cost of staying competitive.

Management maintained full-year FY2026 guidance at the half-year stage: low single-digit tobacco net revenue growth, double-digit NGP net revenue growth, adjusted operating profit growth of 3% to 5% at constant currency, and at least high single-digit adjusted EPS growth, with performance weighted towards the second half. The FY2026 year ended on 30 September 2026 and results had not been published at the time of writing.

Cash Generation, the Dividend and the Buyback

Cash conversion is where this business earns its reputation. FY2025 free cash flow was approximately £2.7bn, and over the twelve months to 31 March 2026 free cash flow was around £2.6bn with cash conversion of 98%, despite the Delaware payment. For FY2026 the company has guided to at least £2.2bn of free cash flow after Delaware settlement and 2030 Strategy costs.

That cash funds two things. The FY2025 dividend was 160.32p per share, up 4.5%, paid in quarterly instalments of 40.08p under a progressive dividend policy. The interim dividend was raised a further 4.0% at the FY2026 half-year. Alongside the dividend, Imperial has been buying back stock at scale: a £1.45bn programme is running in FY2026, following roughly £2.8bn returned through dividends and buybacks combined in FY2025.

Leverage sits in the middle of the range for the sector. FY2025 adjusted net debt was £8,406m, up from £7,740m, with the increase driven largely by the buyback, and adjusted net debt to EBITDA stood at 2.0 times. Reported net debt was higher at £8,954m; the difference reflects accrued interest, lease liabilities and certain derivative fair values that the adjusted measure excludes. The practical question for income investors is whether the buyback can continue at this pace without leverage drifting upwards, because the buyback is the mechanism converting flat underlying profit into high single-digit EPS growth.

Valuation: What the Multiples Currently Read

Imperial Brands shares closed at 2,467p, or £24.67, on 6 October 2026 and were trading around 2,490p, or £24.90, on 7 October 2026, giving a market capitalisation of roughly £18.6bn. The 52-week range spans a low of 2,408p against a high of 3,632p, so the shares were recently near the bottom of their one-year range after falling back from the spring.

Set that price against FY2025 adjusted earnings per share of 315.0p and the trailing price-to-earnings ratio works out at roughly 7.9 times. A P/E ratio simply divides the share price by earnings per share, so a reading near eight means the market is paying about eight years of last year's adjusted earnings for a share. Tobacco peers including British American Tobacco (BATS), Philip Morris International (PM) and Altria (MO) have historically traded on low multiples too, which reflects the market's assumption that combustible volumes keep declining. The multiple on its own does not tell you whether that assumption is correctly calibrated.

On the income side, the FY2025 dividend of 160.32p against a share price near 2,490p implies a trailing yield of roughly 6.4%. A dividend yield is the annual dividend divided by the share price, so a yield that high can reflect either a strong payout or a depressed share price, and distinguishing between the two is the analytical work. Dividend cover, which compares earnings per share with the dividend per share, sat at close to two times on FY2025 adjusted EPS of 315.0p against 160.32p paid out.

Risks and What to Watch

The risks here are well known but worth stating plainly. Combustible volumes decline structurally, and FY2025 saw group volume fall 1.7%. Pricing has consistently offset volume losses, but that relationship is not guaranteed and is the single most important mechanism in the model. Regulatory risk is persistent and unpredictable across menthol bans, nicotine caps, flavour restrictions on vapour products and plain packaging. Litigation remains a live cost, as the Delaware settlement charges demonstrate. Currency matters too: Imperial reports in sterling but earns a large share of profit in US dollars and euros, and management flagged a currency headwind on EPS of roughly 2.0% to 2.5% for the first half and 0% to 1% for the full year.

There is also an execution question around NGP. At £368m of net revenue in FY2025, next generation products are not yet large enough to move group profit, and the category has absorbed years of operating losses, though those losses have been reduced by 76% over five years alongside cumulative NGP net revenue growth of 83%. Whether blu, Zone and Pulze reach genuine scale is a multi-year question rather than a half-year one.

The indicators worth tracking are specific. First, aggregate market share across the five priority markets, which is the cleanest read on competitive position. Second, the balance between price and volume in tobacco net revenue. Third, NGP net revenue growth and the trajectory of NGP operating losses. Fourth, free cash flow against the at least £2.2bn FY2026 guide, since that figure underwrites both the dividend and the buyback. Fifth, adjusted net debt to EBITDA against the 2.0 times FY2025 level. And sixth, delivery of the £320m of annual savings targeted by 2030.

Conclusion

What this Imperial Brands stock analysis ultimately rests on is a single tension. The group operates in a category with declining volumes, and it has offset that decline with pricing, cost reduction and a steadily shrinking share count, producing adjusted EPS growth of 9.1% at constant currency in FY2025 and 5.3% in the first half of FY2026 while underlying operating profit moved far less. Cash conversion near 98% has funded a dividend of 160.32p and a £1.45bn buyback simultaneously.

Whether that machinery keeps running is an empirical question, not a matter of opinion, and the evidence will arrive in the reported numbers. If priority-market share holds, pricing continues to outrun volume decline, free cash flow lands at or above £2.2bn and leverage stays near 2.0 times, the model described above remains intact. If share erodes materially in the United States or Germany, if pricing power narrows, or if restructuring and litigation costs run ahead of the guided envelope, the picture changes in ways the low headline multiple does not currently reflect. Those are the lines to watch when FY2026 results are published.